AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36424125 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant nebulisation (SN) at 200 mg/kg (poractant alfa)
Number of subjects: 35
Study 36424125 — intervention group
Group type: COMPARATOR
Intervention: Positive distending pressure alone (Control)
Number of subjects: 35
Study 32974844 — intervention group
Group type: EXPERIMENTAL
Intervention: κ‐selenocarrageenan supplementation at selenium (Se) levels of 2.0 μg/g
Number of subjects: 2
Study 32974844 — intervention group
Group type: COMPARATOR
Intervention: Control diet without supplemented κ‐selenocarrageenan
Number of subjects: 2
Study 32740286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sceletium tortuosum (ST) extract (25-mg) supplementation
Number of subjects: 60
Study 32740286 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study 35331208 — intervention group
Group type: EXPERIMENTAL
Intervention: True Auricular Acupressure (AA)
Number of subjects: 114
Study 35331208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham Auricular Acupressure (AA)
Number of subjects: 114
Study 35331208 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 114
Study 32961514 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A 150 units in one foot and normal saline 0.9% in the other foot (Group D1)
Number of subjects: 141
Study 32961514 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A 150 units in both feet (Group D2)
Number of subjects: 141
Study 32961514 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.9% in both feet (Group N)
Number of subjects: 141
Study 34228677 — intervention group
Group type: EXPERIMENTAL
Intervention: IER reinforcement
Number of subjects: 73
Study 34228677 — intervention group
Group type: COMPARATOR
Intervention: No IER reinforcement
Number of subjects: 73
Study 32163634 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive periodontal surgery (MIS) with enamel matrix derivative (EMD)
Number of subjects: 38
Study 32163634 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive periodontal surgery (MIS)
Number of subjects: 38
Study 34315357 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective grading system using AOS® Anterior software
Number of subjects: 300
Study 34315357 — intervention group
Group type: COMPARATOR
Intervention: Subjective grading using a 0-4 Efron grading scale
Number of subjects: 300
Study 34315357 — intervention group
Group type: COMPARATOR
Intervention: Subjective methods
Number of subjects: 300
Study 32306803 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose multi-strain probiotic (5 billion CFU)
Number of subjects: 0
Study 32306803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose multi-strain probiotic (25 billion CFU)
Number of subjects: 0
Study 32306803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37962104 — intervention group
Group type: COMPARATOR
Intervention: Primary wound closure (Control group)
Number of subjects: 40
Study 37962104 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive open healing (Test group)
Number of subjects: 40
Study 33629921 — intervention group
Group type: EXPERIMENTAL
Intervention: QX003S (8 mg/kg)
Number of subjects: 80
Study 33629921 — intervention group
Group type: COMPARATOR
Intervention: Actemra®
Number of subjects: 80
Study 33629921 — intervention group
Group type: EXPERIMENTAL
Intervention: QX003S
Number of subjects: 80
Study 36606270 — intervention group
Group type: EXPERIMENTAL
Intervention: WeiNaoKang (SaiLuoTong)
Number of subjects: 62
Study 36606270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 36606270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral perfusion (intervention group n=7)
Number of subjects: 62
Study 32691938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequencing treatment of oral oxybutynin chloride after BTX‐A injections
Number of subjects: 0
Study 32691938 — intervention group
Group type: COMPARATOR
Intervention: Oral oxybutynin chloride in monotherapy
Number of subjects: 0
Study 34415640 — intervention group
Group type: EXPERIMENTAL
Intervention: 20g carbohydrate breakfast
Number of subjects: 31
Study 34415640 — intervention group
Group type: EXPERIMENTAL
Intervention: 50g carbohydrate breakfast
Number of subjects: 31
Study 34415640 — intervention group
Group type: EXPERIMENTAL
Intervention: 100g carbohydrate breakfast
Number of subjects: 31
Study 34415640 — intervention group
Group type: EXPERIMENTAL
Intervention: 150g carbohydrate breakfast
Number of subjects: 31
Study 34415640 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of glucose excursion patterns
Number of subjects: 31
Study 33989683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic vitreolysis (PVL) using perfluoropropane (C3F8) gas
Number of subjects: 81
Study 33989683 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (observation)
Number of subjects: 81
Study 32348007 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus Berberine (BA group)
Number of subjects: 658
Study 32348007 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline plus Furazolidone (TF group)
Number of subjects: 658
Study 34799132 — intervention group
Group type: EXPERIMENTAL
Intervention: Salad with canola oil emulsion and black pepper (COE + BP)
Number of subjects: 0
Study 34799132 — intervention group
Group type: EXPERIMENTAL
Intervention: Salad with black pepper (BP)
Number of subjects: 0
Study 34799132 — intervention group
Group type: EXPERIMENTAL
Intervention: Salad with canola oil emulsion (COE)
Number of subjects: 0
Study 35830636 — intervention group
Group type: EXPERIMENTAL
Intervention: calcium glycerophosphate (CaGP)
Number of subjects: 53
Study 35830636 — intervention group
Group type: EXPERIMENTAL
Intervention: casein phosphopeptide amorphous calcium fluoride phosphate (CPP‐ACFP)
Number of subjects: 53
Study 35830636 — intervention group
Group type: COMPARATOR
Intervention: 1450 ppm fluoride toothpaste (Control)
Number of subjects: 53
Study 33262012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 120
Study 33262012 — intervention group
Group type: COMPARATOR
Intervention: Oral acetaminophen
Number of subjects: 120
Study 32144883 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS + CT
Number of subjects: 18
Study 32144883 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + CT
Number of subjects: 18
Study 35766242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory integration therapy delivered over 26 weeks
Number of subjects: 138
Study 35766242 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study 35766242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory integration therapy
Number of subjects: 138
Study 33140542 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide (1.8 mg/day)
Number of subjects: 35
Study 33190575 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of cocoa-rich chocolate (99%) daily for 6 months
Number of subjects: 140
Study 33190575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study 34376190 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency STN-DBS (60 Hz)
Number of subjects: 14
Study 34376190 — intervention group
Group type: COMPARATOR
Intervention: High-frequency STN-DBS
Number of subjects: 14
Study 32840418 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (600 mg twice per day)
Number of subjects: 375
Study 32840418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 33899689 — intervention group
Group type: EXPERIMENTAL
Intervention: CALAS (Capsule of alkaloids from Alstonia scholaris leaves)
Number of subjects: 62
Study 33899689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 33899689 — intervention group
Group type: EXPERIMENTAL
Intervention: CALAS
Number of subjects: 62
Study 35241252 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy plus pembrolizumab and trametinib
Number of subjects: 0
Study 35241252 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic body radiotherapy plus gemcitabine
Number of subjects: 0
Study 34272955 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic corpus generated by GPT-2
Number of subjects: 500
Study 34272955 — intervention group
Group type: COMPARATOR
Intervention: Natural corpus
Number of subjects: 500
Study 34272955 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented method combining natural and synthetic corpora
Number of subjects: 500
Study 33369791 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized CO rebreathing (oCOR)
Number of subjects: 11
Study 33369791 — intervention group
Group type: EXPERIMENTAL
Intervention: Procnew15s (single inhalation of CO bolus with 15s breath hold)
Number of subjects: 11
Study 33369791 — intervention group
Group type: EXPERIMENTAL
Intervention: Procnew30s (single inhalation of CO bolus with 30s breath hold)
Number of subjects: 11
Study 36088313 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multidisciplinary vocational rehabilitation program
Number of subjects: 770
Study 36088313 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 770
Study 32868637 — intervention group
Group type: COMPARATOR
Intervention: Resveratrol 2.5 g + 0 mg piperine
Number of subjects: 24
Study 32868637 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 2.5 g + 5 mg piperine
Number of subjects: 24
Study 32868637 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 2.5 g + 25 mg piperine
Number of subjects: 24
Study 36384321 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural hypertonic saline injection (5%)
Number of subjects: 0
Study 36384321 — intervention group
Group type: COMPARATOR
Intervention: Foot acupoints hypertonic saline injection (5%)
Number of subjects: 0
Study 34627152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile video-based education session (Truth About Low Back Pain)
Number of subjects: 208
Study 34627152 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 208
Study 32876139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber levels 2.78%
Number of subjects: 480
Study 32876139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber levels 3.08%
Number of subjects: 480
Study 32876139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber levels 3.38%
Number of subjects: 480
Study 32876139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber levels 3.68%
Number of subjects: 480
Study 32876139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber levels 3.98%
Number of subjects: 480
Study 32876139 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary fiber levels
Number of subjects: 480
Study 35639723 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 nm-wavelength invasive laser acupuncture (ILA)
Number of subjects: 45
Study 35639723 — intervention group
Group type: EXPERIMENTAL
Intervention: 830 nm-wavelength invasive laser acupuncture (ILA)
Number of subjects: 45
Study 35639723 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham laser)
Number of subjects: 45
Study 34553296 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib+capecitabine (N+C)
Number of subjects: 202
Study 34553296 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib+capecitabine (L+C)
Number of subjects: 202
Study 35331536 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavonoid cocoa (10.79 mg/g)
Number of subjects: 30
Study 35331536 — intervention group
Group type: COMPARATOR
Intervention: Low flavonoid cocoa (1.02 mg/g)
Number of subjects: 30
Study 33795646 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Ketamine
Number of subjects: 0
Study 33795646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32452060 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized 0.5-mm micropunch grafting (epidermal orientation)
Number of subjects: 50
Study 32452060 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized 0.5-mm micropunch grafting (dermal orientation)
Number of subjects: 50
Study 36012924 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (STAG)
Number of subjects: 75
Study 36012924 — intervention group
Group type: COMPARATOR
Intervention: Soft tissue (STG)
Number of subjects: 75
Study 36012924 — intervention group
Group type: COMPARATOR
Intervention: Articulatory (AG)
Number of subjects: 75
Study 32895455 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, bortezomib, and dexamethasone (PVd)
Number of subjects: 226
Study 33503289 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPN-101 (3 mg/kg SC)
Number of subjects: 0
Study 33503289 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPN-101 (10 mg/kg IV)
Number of subjects: 0
Study 33503289 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPN-101 (1 mg/kg IV, 4 weekly doses)
Number of subjects: 0
Study 33503289 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPN-101 (various doses)
Number of subjects: 0
Study 33503289 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPN-101
Number of subjects: 0
Study 34980505 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) with high-titre neutralizing anti-SARS-CoV-2 antibodies (CCP), administered in a maximum of three therapeutic fractions (TFs) over 3-5 days, with a neutralizing antibody titre of = 1:160 or = 1:80 if unavailable.
Number of subjects: 1517
Study 34980505 — intervention group
Group type: COMPARATOR
Intervention: Convalescent plasma (CP) with high-titre neutralizing anti-SARS-CoV-2 antibodies (CCP)
Number of subjects: 1517
Study 33653964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated IG-VMAT (HFRT; 70 Gy/28 fractions over 5.5 weeks)
Number of subjects: 92
Study 33653964 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated IG-VMAT (CFRT; 80 Gy/40 fractions over 8 weeks)
Number of subjects: 92
Study 33653964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated IG-VMAT (HFRT)
Number of subjects: 92
Study 33653964 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated IG-VMAT (CFRT)
Number of subjects: 92
Study 32811378 — intervention group
Group type: EXPERIMENTAL
Intervention: DOSE1 (1 hour, 5 days/week, more than double the intensity of Control)
Number of subjects: 75
Study 32811378 — intervention group
Group type: EXPERIMENTAL
Intervention: DOSE2 (2 hours, 5 days/week, more than quadruple the intensity of Control)
Number of subjects: 75
Study 32811378 — intervention group
Group type: EXPERIMENTAL
Intervention: DOSE2
Number of subjects: 75
Study 32811378 — intervention group
Group type: EXPERIMENTAL
Intervention: DOSE1 and DOSE2
Number of subjects: 75
Study 32811378 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care physical therapy: 1 hour, 5 days/week)
Number of subjects: 75
Study 34617309 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prednisolone (0.75 mg/kg/day)
Number of subjects: 72
Study 34617309 — intervention group
Group type: COMPARATOR
Intervention: Intermittent prednisolone (0.75 mg/kg/day for first 10 days of every month)
Number of subjects: 72
Study 33334404 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (NH)
Number of subjects: 16
Study 33334404 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 16
Study 33334404 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia (NN)
Number of subjects: 16
Study 33334404 — intervention group
Group type: COMPARATOR
Intervention: Hypobaric normoxia (HN)
Number of subjects: 16
Study 34016017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation intervention focusing on psychological ownership
Number of subjects: 2012
Study 34016017 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher individual psychological ownership
Number of subjects: 2012
Study 34016017 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective psychological ownership
Number of subjects: 2012
Study 34416949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard cookies baked at 185 °C for 16 min
Number of subjects: 0
Study 34416949 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft cookies baked at 165.6 °C for 22 min
Number of subjects: 0
Study 34416949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard cookie dough at 60 °C, 65 °C, and 70 °C
Number of subjects: 0
Study 34416949 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft cookie dough at 60 °C, 65 °C, and 70 °C
Number of subjects: 0
Study 34416949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard cookie dough
Number of subjects: 0
Study 34416949 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft cookie dough
Number of subjects: 0
Study 36399899 — intervention group
Group type: EXPERIMENTAL
Intervention: Just Do You (JDY)
Number of subjects: 121
Study 33624200 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 2780 nm
Number of subjects: 60
Study 33624200 — intervention group
Group type: COMPARATOR
Intervention: Diode laser at 940 nm
Number of subjects: 60
Study 32814747 — intervention group
Group type: EXPERIMENTAL
Intervention: HK‐LS HS‐1 supplement
Number of subjects: 10
Study 32814747 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 35169280 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat treatment group
Number of subjects: 100
Study 35169280 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonpharmacological lifestyle modification for hyperuricemia)
Number of subjects: 100
Study 33569589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonformal education activities
Number of subjects: 581
Study 35793182 — intervention group
Group type: EXPERIMENTAL
Intervention: PKP + LAI (lidocaine + triamcinolone acetonide injections)
Number of subjects: 150
Study 35793182 — intervention group
Group type: COMPARATOR
Intervention: PKP
Number of subjects: 150
Study 35793182 — intervention group
Group type: EXPERIMENTAL
Intervention: PKP + LAI
Number of subjects: 150
Study 34085471 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 278
Study 34085471 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 278
Study 32134293 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling and feedback (MF)
Number of subjects: 187
Study 32134293 — intervention group
Group type: EXPERIMENTAL
Intervention: Gesture feedback (GF)
Number of subjects: 187
Study 32134293 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial language feedback (SLF)
Number of subjects: 187
Study 32134293 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control
Number of subjects: 187
Study 35953356 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram combining clinical factors and RadScores
Number of subjects: 267
Study 35953356 — intervention group
Group type: COMPARATOR
Intervention: Clinical factor models
Number of subjects: 267
Study 34417399 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel anti-regurgitation (AR) formula containing 0.4g/100mL locust bean gum, partly fermented formula with postbiotics, scGOS and lcFOS (0.4g/100mL, ratio 9:1)
Number of subjects: 182
Study 34417399 — intervention group
Group type: COMPARATOR
Intervention: Control AR formula containing 0.4g/100mL locust bean gum with postbiotics
Number of subjects: 182
Study 32040028 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel resistance exercise training (ETG; n = 18)
Number of subjects: 36
Study 32040028 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n = 18)
Number of subjects: 36
Study 34571091 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy (75 mg/m2 cisplatin and 75 mg/m2 docetaxel on day 1 and 750 mg/m2 fluorouracil from the first to the fifth day)
Number of subjects: 44
Study 34487651 — intervention group
Group type: COMPARATOR
Intervention: Conventional knot tying plus electrocautery (Group C)
Number of subjects: 180
Study 34487651 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced compressive energy sources (Ultrasonic Scalpel and Ligasure) (Group H)
Number of subjects: 180
Study 34487651 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced compressive energy sources (Group H)
Number of subjects: 180
Study 34487651 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemostasis techniques (Group H)
Number of subjects: 180
Study 33370132 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster Care Group (FCG)
Number of subjects: 136
Study 33370132 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual Group (CAUG)
Number of subjects: 136
Study 33370132 — intervention group
Group type: COMPARATOR
Intervention: Never-institutionalized community comparison children
Number of subjects: 136
Study 35259529 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) plus standard of care (SoC)
Number of subjects: 86
Study 35259529 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 86
Study 33825795 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush Up mobile application (Group 1)
Number of subjects: 247
Study 33825795 — intervention group
Group type: COMPARATOR
Intervention: Educative video (Group 2)
Number of subjects: 247
Study 33825795 — intervention group
Group type: COMPARATOR
Intervention: Manual demonstration (Group 3)
Number of subjects: 247
Study 34491123 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib (320 mg once daily or 160 mg twice daily)
Number of subjects: 0
Study 34491123 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 0
Study 33617042 — intervention group
Group type: EXPERIMENTAL
Intervention: CJM112 15 mg, 50 mg, and 150 mg subcutaneous (s.c.)
Number of subjects: 96
Study 33617042 — intervention group
Group type: EXPERIMENTAL
Intervention: CJM112 450 mg subcutaneous (s.c.)
Number of subjects: 96
Study 33617042 — intervention group
Group type: EXPERIMENTAL
Intervention: CJM112 150 mg high frequency
Number of subjects: 96
Study 33617042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 33617042 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg subcutaneous (s.c.)
Number of subjects: 96
Study 32875419 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile exploration (combined manual and visual exploration)
Number of subjects: 20
Study 32875419 — intervention group
Group type: COMPARATOR
Intervention: Visual exploration only (control group)
Number of subjects: 20
Study 32067628 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 32067628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0